Marc Beer Renovia is undoubtedly a man of many talents. As the CEO of Renovia Inc., the ambitious and creative entrepreneur recently grabbed the limelight after proceeding with the distribution of exceptional products tailored to treat pelvic floor disorders. Such a noble cause comes in the wake of an impressive $32 million funding from the Series B round topped up with an extra $10 million on venture debt.
Based in Boston, the MedTech enterprise has consistently developed a stellar reputation for going above and beyond to develop therapeutic drugs to relieve pelvic floor conditions such as urinary continence that has been reported to plague over 250 million female patients worldwide. The company’s flagship product, Leva, recently received FDA approval and is expected to begin mass production.
Renovia’s remarkable success wouldn’t have been possible without the immense contribution of various stakeholders such as the Longwood Fund. As a healthcare-based investment enterprise, the Longwood Fund is widely credited for their substantial donation as well as bringing on board equally interested institutions such as Ascension Ventures and Perceptive Advisors. Donations obtained will undoubtedly go a long way in testing and developing therapeutic drugs with an eye to harnessing the Leva device.
According to Marc Beer Renovia, the enterprise couldn’t have been more grateful to have the support of its esteemed investors to play a critical role in the treatment of pelvic floor conditions. More importantly, the partnership is expected to harness innovation and proprietary sensor technologies with an eye to providing customers with vital information in the development of modern treatment options. By developing groundbreaking technologies, the company looks forward to providing affordable healthcare costs.
Marc Beer Renovia’s Profile
Marc Beer Renovia is widely considered to be a celebrated healthcare expert. With over two decades’ worth of experience, he has proven to be an influential asset in the development and commercialization of pharmaceuticals, diagnostics, and biotechnology. Before founding Renovia Inc., Marc Beer built an impressive resume that elevated his career to astronomical success. For starters, the entrepreneur once served as ViaCell’s CEO, a position that demanded immense responsibility and expertise in the development of rare disease drugs.
Before holding such a position, Marc Beer Renovia also served as the Vice President of Global Marketing at Genzyme. While serving in this capacity, Marc Beer was tasked with spurring sales and marketing endeavors in the company’s Abbott Laboratories’ branch. Alternatively, he had also served as an influential member of the Mass Life Science Board of Commonwealth Board. Learn more: https://www1.salary.com/Marc-Beer-Salary-Bonus-Stock-Options-for-AEGERION-PHARMACEUTICALS-INC.html